TransMedics Group, Inc. (TMDX)

Market Cap	2.41B
Revenue (ttm)	401.09M
Net Income (ttm)	32.64M
Shares Out	33.56M
EPS (ttm)	0.94
PE Ratio	76.78
Forward PE	65.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,180,544
Open	75.89
Previous Close	75.45
Day's Range	71.50 - 76.78
52-Week Range	55.00 - 177.37
Beta	2.11
Analysts	Buy
Price Target	116.10 (+61.36%)
Earnings Date	Feb 27, 2025

About TMDX

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung trans...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 2, 2019
• Employees: 584
• Stock Exchange: NASDAQ
• Ticker Symbol: TMDX
• Website: https://www.transmedics.com

Financial Performance

In 2023, TransMedics Group's revenue was $241.62 million, an increase of 158.53% compared to the previous year's $93.46 million. Losses were -$25.03 million, -30.92% less than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is $116.1, which is an increase of 61.36% from the latest price.

Price Target

$116.1

(61.36% upside)

Analyst Consensus: Buy